ArticleInternational journal of molecular sciences2025
Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviated the Inflammatory Response in Mice Infected with the Influenza Virus A (H1N1).
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimized CoQ10 deliveryRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Influenza A virus (H1N1) infection poses a significant global public health challenge and imposes a substantial economic burden. Numerous studies have shown that excessive immune activation and dysregulated inflammatory responses following influenza virus infection are the primary causes of disease progression and mortality. Extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) exhibit potent anti-inflammatory effects. Therefore, this study aims to investigate the effects of extracellular vesicles derived from human umbilical cord mesenchymal stem cells (hUCMSC-EVs) on pulmonary inflammatory responses in mice infected with the influenza A virus (H1N1). The study first established a mouse influenza virus infection model by intranasal inoculation of the influenza A virus (H1N1), followed by treatment with hUCMSC-EVs (70 μg) administered via tail vein injection for four consecutive days. The results showed that compared with the H1N1 group, after treatment with hUCMSC-EVs, pulmonary edema was reduced, inflammatory cell infiltration in the lungs was significantly decreased, and the expression levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) proteins in serum and lung tissue were significantly reduced. Therefore, this study suggests that the protective effect of hUCMSC-EVs against lung damage caused by influenza A virus (H1N1) infection may be related to the reduction in inflammatory cytokine levels of TNF-α, IL-1β, and IL-6, thereby alleviating pulmonary inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.